Search - tctmd.com

Displaying 561 - 580 of 633

Sort: Relevancy | Date

News Daily News

High-Sensitivity Troponin I Assay May Rule Out MI in Large Number of Patients

Todd Neale

October 13, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

Contrary to Expectations, Study Finds No Sex Difference in Coronary Microvascular Dysfunction

Yael L. Maxwell

September 23, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Daily News

Registry Charts Trends in Mechanical Circulatory Support During PCI

L.A. McKeown

September 14, 2015

News Daily News

COURAGE Analysis: Patients With Lower Exercise Capacity No More Likely to Benefit from Revascularization

L.A. McKeown

September 09, 2015

News Daily News

Análisis del COURAGE: Los Pacientes con una Menor Capacidad de Hacer Ejercicio No son Más Propensos a Beneficiarse de la Revascularización

L.A. McKeown

September 09, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Industry News

Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes

August 26, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

Cardiac Rehab After Acute MI Still Underutilized in Older Patients

Yael L. Maxwell

August 07, 2015

News Daily News

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

August 06, 2015

News Daily News

Subestudio del COURAGE: La PCI No Ofrece Beneficio Añadido sobre, Solo, el Tratamiento Médico Óptimo, ni en Hombres ni en Mujeres

L.A. McKeown

August 03, 2015

News Daily News

COURAGE Substudy: PCI Adds No Overall Benefit to OMT Alone in Either Women or Men

L.A. McKeown

August 03, 2015

News Daily News

FDA Approves Heart Failure Drug That Comes With Survival Benefit

Todd Neale

July 13, 2015

News Industry News

CCTA and MPI in acute chest pain patients yield similar outcomes, resource use

June 17, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

Advertisement

High-Sensitivity Troponin I Assay May Rule Out MI in Large Number of Patients

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Contrary to Expectations, Study Finds No Sex Difference in Coronary Microvascular Dysfunction

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Registry Charts Trends in Mechanical Circulatory Support During PCI

COURAGE Analysis: Patients With Lower Exercise Capacity No More Likely to Benefit from Revascularization

Análisis del COURAGE: Los Pacientes con una Menor Capacidad de Hacer Ejercicio No son Más Propensos a Beneficiarse de la Revascularización

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

Researchers Use Quanterix’s Simoa Technology to Detect Early Indicators of Potential Adverse Cardiovascular Outcomes

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Cardiac Rehab After Acute MI Still Underutilized in Older Patients

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

Subestudio del COURAGE: La PCI No Ofrece Beneficio Añadido sobre, Solo, el Tratamiento Médico Óptimo, ni en Hombres ni en Mujeres

COURAGE Substudy: PCI Adds No Overall Benefit to OMT Alone in Either Women or Men

FDA Approves Heart Failure Drug That Comes With Survival Benefit

CCTA and MPI in acute chest pain patients yield similar outcomes, resource use

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content